Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelcitoclax added to azacitidine + venetoclax for selected acute myeloid leukemia in the ADAPT platform
ACTRN12625000994482Phase 2Not yet recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pelcitoclax in acute myeloid leukemia (AML), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Maximum tolerated dose of pelcitoclax, Overall survival in Domain 1 and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
pelcitoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12625000994482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000994482.